The future direction for Laboratorios Farmacéuticos Rovi, S.A. will depend largely on whether the Spanish drugmaker is tempted to sell its successful contract development and manufacturing organization (CDMO) and possibly pocket well over €3bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?